secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2023-02-02T23:59:59+00:00
Accession:  0001628280-23-002041
Event type: leadership
Sentiment:  negative
Materiality: 0.55
Item codes: 5.02, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics CMO Adam Crystal resigns; Hagop Youssoufian named interim CMO
-----------------------------------------------------------------------------

- Adam S. Crystal, M.D., Ph.D., resigns as CMO effective Feb 24, 2023 to pursue a head of R&D opportunity elsewhere.
- Crystal will provide transitional consulting services on an as-needed basis until Sep 1, 2023.
- Hagop Youssoufian, M.D., appointed interim CMO effective Feb 24, 2023; permanent search underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828023002041/0001628280-23-002041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828023002041/cccc-20230130.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-002041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer